DEVELOPMENT OF EXTRA-MUSCULOSKELETAL MANIFESTATIONS IN UPADACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
Abstract: OP0061
Authors: Poddubnyy D et al.
Key content:
The current analysis is based on data from the upadacitinib clinical trial program including 2 PsA trials, 2 AS trials and one nr-axSpA trial. All trials were double blinded and placebo-controlled for a short time period, then followed by an extension period where all patients received upadacitinib. Uveitis, inflammatory bowel disease (IBD) and psoriasis were recorded as treatment-emerging adverse events (with the exception of psoriasis within the PsA trials).
The vast majority of patients did not have a history of previous extra-musculoskeletal mani-festations (EMM) at baseline. In PsA studies, development of uveitis and IBD was low inde-pendent of prior history or treatment. In AS, development of uveitis was numerically higher in patients on placebo (7.5 E/100 PY, 95%CI 2.7-16.3 versus 2.8 E/100 PY, 95%CI 1.8-4.1) and in patients with a previous history of uveitis compared to patients who did not have a history of uveitis. IBD and psoriasis were infrequent regardless of treatment and prior history. In nr-axSpA, development of uveitis was low regardless of prior history, but the total rate was higher in patients on placebo (2.1 [0.4, 6.3]) vs UPA15 (0.9 [0.2, 2.7]); occurrence of IBD and psoriasis were low or absent.
Data from this post-hoc analysis report the occurrence of EMMs in the SELECT program with the limitation, that these with specific EMMs were not systematically evaluated.
Relevance:
The occurrence of EMMs in patients treated with UPA15 was generally low across PsA, AS, and nr-axSpA. Uveitis was numerically higher in patients treated with placebo versus UPA, and particularly in patients with AS. This data suggest that JAK inhibitors might represent an interesting treatment option in patients with a higher risk of uveitis.
